Acumen Pharmaceuticals (ABOS) Cash from Operations (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Cash from Operations data on file, last reported at 24128000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 29.29% year-over-year to 24128000.0; the trailing twelve-month figure through Mar 2026 stood at 105545000.0 (down 2.99% YoY), and the FY2025 full-year result was 115538000.0, down 34.01% from the prior year.
• Cash from Operations retreated to 24128000.0 in Q1 2026, from 19096000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 6468000.0 in Q2 2022 to a low of 34121000.0 in Q1 2025.
• A 5-year average of 17888117.65 and a median of 16545000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations plunged 250.17% in 2022 and grew 29.83% in 2025, its largest moves.
• Tracing ABOS's Cash from Operations over 5 years: stood at 11203000.0 in 2022, then climbed by 25.79% to 8314000.0 in 2023, then sank by 227.34% to 27215000.0 in 2024, then gained by 29.83% to 19096000.0 in 2025, then fell by 26.35% to 24128000.0 in 2026.
• Business Quant data shows ABOS's Cash from Operations at 24128000.0 in Q1 2026, 19096000.0 in Q4 2025, and 30489000.0 in Q3 2025.